Drug-drug interactions involving membrane transporters in the human kidney

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 4, 2006, Pages 505-532

  Li, Meng ^a   Anderson, Gail D ^a   Wang, Joanne ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug interactions; Drug transporters; Kidney; Organic anion transporters; Organic cation transporters; Pharmacokinetics

Indexed keywords

CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; ITRACONAZOLE; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PROPAFENONE; QUINIDINE; RITONAVIR; TRIMETHOPRIM; VALSPODAR; VERAPAMIL; CARRIER PROTEIN; DRUG;

DRUG ANTAGONISM; DRUG ELIMINATION; HUMAN; KIDNEY; PROTEIN TRANSPORT; REVIEW; CHEMISTRY; DRUG INTERACTION; GENETICS; METABOLISM;

DRUG INTERACTIONS; HUMANS; KIDNEY; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS;

EID: 33747834042     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.4.505     Document Type: Review

References (232)

1. SHITARA Y, SATO H, SUGIYAMA Y: Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Ann. Rev. Pharmacol. Toxicol. (2005) 45:689-723.
2. TSUJI A: Transporter-mediated drug interactions. Drug Metab. Pharmacokinet. (2002) 17(4):253-274.
3. ENDUES CJ, HSIAO P, CHUNG FS, UNADKAT JD: The role of transporters in drug interactions. Eur J. Pharm. Sci. (2006) 27(5):501-517.
4. BONATE PL, REITH K, WEIR S: Drug interactions at the renal level. Implications for drug development. Clin. Pharmacokinet. (1998) 34(5):375-404.
5. PRITCHARD JB, MILLER DS: Mechanisms mediating renal secretion of organic anions and cations. Physiol. Rev. (1993) 73(4):765-796.
6. WRIGHT SH, DANTZLER WH: Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev. (2004) 84(3):987-1049.
7. ZHANG L, BRETT CM, GIACOMINI KM: Role of organic cation transporters in drug absorption and elimination. Ann. Rev. Pharmacol. Toxicol. (1998) 38:431-460.
8. LEIBACH FH, GANAPATHY V: Peptide transporters in the intestine and the kidney. Ann. Rev. Nutr. (1996) 16:99-119.
9. KONG W, ENGEL K, WANG J: Mammalian nucleoside transporters. Curr. Drug Metab. (2004) 5(1):63-84.
10. INUI KI, MASUDA S, SAITO H: Cellular and molecular aspects of drug transport in the kidney. Kidney Int. (2000) 58(3):944-958.
11. LEE W, KIM RB: Transporters and renal drug elimination. Ann. Rev. Pharmacol. Toxicol. (2004) 44:137-166.
12. MASEREEUW R, RUSSEL FG: Mechanisms and clinical implications of renal drug excretion. Drug Metab. Rev. (2001) 33(3-4):299-351.
13. OTSUKA M, MATSUMOTO T, MORIMOTO R et al.: A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA (2005) 102(50):17923-17928.
14. SEKINE T, MIYAZAKI H, ENDOU H: Molecular physiology of renal organic anion transporters. Am. J. Physiol. Renal Physiol. (2006) 290(2):F251-F261.
15. YOU G: Structure, function, and regulation of renal organic anion transporters. Med. Res. Rev. (2002) 22(6):602-616.
16. RUSSEL FG, MASEREEUW R, VAN AUBEL RA: Molecular aspects of renal anionic drug transport. Ann. Rev. Physiol. (2002) 64:563-594.
17. SUN W, WU RR, VAN POELJE PD, ERION MD: Isolation of a family of organic anion transporters from human liver and kidney. Biochem. Biophys. Res. Commun. (2001) 283(2):417-422.
18. MOTOHASHI H, SAKURAI Y, SAITO H et al.: Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. (2002) 13(4):866-874.
19. BAKHIYA A, BAHN A, BURCKHARDT G, WOLFF N: Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Pysiol. Biochem. (2003) 13(5):249-256.
20. DRESSER MJ, LEABMAN MK, GIACOMINI KM: Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. (2001) 90(4):397-421.
21. TAKEDA M, NARIKAWA S, HOSOYAMADA M et al.: Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur. J. Pharmacol. (2001) 419(2-3):113-120.
22. BABU E, TAKEDA M, NARIKAWA S et al.: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim. Biophys. Acta (2002) 1590(1-3):64-75.
23. CHA SH, SEKINE T, KUSUHARA H et al.: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J. Biol. Chem. (2000) 275(6):4507-4512.
24. EKARATANAWONG S, ANZAI N, JUTABHA P et al.: Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J. Pharmacol. Sci. (2004) 94(3):297-304.
25. HAGENBUCH B, MEIER PJ: Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. (2004) 447(5):653-665.
26. HAGENBUCH B, MEIER PJ: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta (2003) 1609(1):1-18.
27. TAMAI I, NEZU J, UCHINO H et al.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. (2000) 273(1):251-260.
28. MIKKAICHI T, SUZUKI T, ONOGAWA T et al.: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc. Natl. Acad. Sci. USA (2004) 101(10):3569-3574.
29. VAN DE WATER FM, MASEREEUW R, RUSSEL FG: Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug Metab. Rev. (2005) 37(3):443-471.
30. VAN AUBEL RA, SMEETS PH, PETERS JG, BINDELS RJ, RUSSEL FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. (2002) 13(3):595-603.
31. SCHAUB TP, KARTENBECK J, KONIG J et al.: Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. (1999) 10(6):1159-1169.
32. SMEETS PH, VAN AUBEL RA, WOUTERSE AC, VAN DEN HEUVEL JJ, RUSSEL FG: Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J. Am. Soc. Nephrol. (2004) 15(11):2828-2835.
33. VAN AUBEL RA, SMEETS PH, VAN DEN HEUVEL JJ, RUSSEL FG: Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal Physiol. (2005) 288(2):F327-F333.
34. KOEPSELL H, ENDOU H: The SLC22 drug transporter family. Pflugers Arch. (2004) 447(5):666-676.
35. FUJITA T, URBAN TJ, LEABMAN MK, FUJITA K, GIACOMINI KM: Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci. (2006) 95(1):25-36.
36. WU X, HUANG W, GANAPATHY ME et al.: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am. J. Physiol. Renal Physiol. (2000) 279(3):F449-F458.
37. +)-coupled transport of L-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney. Biochim. Biophys. Acta (2001) 1512(2):273-284.
38. TAMAI I, NAKANISHI T, KOBAYASHI D et al.: Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations. Mol. Pharm. (2004) 1(1):57-66.
39. YABUUCHI H, TAMAI I, NEZU J et al.: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. (1999) 289(2):768-773.
40. GRUNDEMANN D, HARLFINGER S, GOLZ S et al.: Discovery of the ergothioneine transporter. Proc. Natl. Acad. Sci. USA (2005) 102(14):5256-5261.
41. TAMAI I, OHASHI R, NEZU J et al.: Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem. (1998) 273(32):20378-20382.
42. WU X, HUANG W, PRASAD PD et al.: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J. Pharmacol. Exp. Ther. (1999) 290(3):1482-1492.
43. AMBUDKAR SV, DEY S, HRYCYNA CA et al.: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol. Toxicol. (1999) 39:361-398.
44. LIN JH, YAMAZAKI M: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. (2003) 42(1):59-98.
45. THIEBAUT F, TSURUO T, HAMADA H et al.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA (1987) 84(21):7735-7738.
46. DANIEL H, KOTTRA G: The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. (2004) 447(5):610-618.
47. SHEN H, SMITH DE, YANG T et al.: Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am. J. Physiol. (1999) 276(5 Pt 2):F658-F665.
48. KLAPPER M, DANIEL H, DORING F: Cytosolic COOH terminus of the peptide transporter PEPT2 is involved in apical membrane localization of the protein. Am. J. Physiol. Cell Physiol. (2006) 290(2):C472-C483.
49. LI M, ANDERSON GD, PHILLIPS BR et al.: Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab. Dispos. (2006) 34(4):547-555.
50. GARRIGUES TM, MARTIN U, PERIS-RIBERA JE, PRESCOTT LF: Dose-dependent absorption and elimination of cefadroxil in man. Eur. J. Clin. Pharmacol. (1991) 41(2):179-183.
51. GARCIA-CARBONELL MC, GRANERO L, TORRES-MOLINA F et al.: Nonlinear pharmacokinetics of cefadroxil in the rat. Drug Metab. Dispos. (1993) 21(2):215-217.
52. SUN H, FRASSETTO L, BENET LZ: Effects of renal failure on drug transport and metabolism. Pharmacol. Ther. (2006) 109(1-2):1-11.
53. BARZA M, WEINSTEIN L: Pharmacokinetics of the penicillins in man. Clin. Pharmacokinet. (1976) 1(4):297-308.
54. WEINER IM, WASHINGTON JA 2nd, MUDGE GH: On the mechanism of action of probenecid on renal tubular secretion. Bull. Johns Hopkins Hosp. (1960) 106:333-346.
55. SOMOGYI A: Renal transport of drugs: specificity and molecular mechanisms. Clin. Exp. Pharmacol. Physiol. (1996) 23(10-11):986-989.
56. CARANASOS GJ, STEWART RB, CLUFF LE: Clinically desirable drug interactions. Ann. Rev. Pharmacol. Toxicol. (1985) 25:67-95.
57. BROWN GR: Cephalosporin-probenecid drug interactions. Clin. Pharmacokinet. (1993) 24(4):289-300.
58. CUNNINGHAM RF, ISRAILI ZH, DAYTON PG: Clinical pharmacokinetics of probenecid. Clin. Pharmacokinet. (1981) 6(2):135-151.
59. ENOMOTO A, TAKEDA M, SHIMODA M et al.: Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J. Pharmacol. Exp. Ther. (2002) 301(3):797-802.
60. EMANUELSSON BM, BEERMANN B, PAALZOW LK: Non-linear elimination and protein binding of probenecid. Eur. J. Clin. Pharmacol. (1987) 32(4):395-401.
61. BARBHAIYA R, THIN RN, TURNER P, WADSWORTH J: Clinical pharmacological studies of amoxycillin: effect of probenecid. Br. J. Vener. Dis. (1979) 55(3):211-213.
62. BROWN G, ZEMCOV SJ, CLARKE AM: Effect of probenecid on cefazolin serum concentrations. J. Antimicrob. Chemother. (1993) 31(6):1009-1011.
63. REIN MF, WESTERVELT FB, SANDE MA: Pharmacodynamics of cefazolin in the presence of normal and impaired renal function. Antimicrob. Agents Chemother. (1973) 4(3):366-371.
64. SPINA SP, DILLON EC Jr: Effect of chronic probenecid therapy on cefazolin serum concentrations. Ann. Pharmacother. (2003) 37(5):621-624.
65. SAKURAI Y, MOTOHASHI H, UEO H et al.: Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm. Res. (2004) 21(1):61-67.
66. JUNG KY, TAKEDA M, SHIMODA M et al.: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. (2002) 70(16):1861-1874.
67. UEO H, MOTOHASHI H, KATSURA T, INUI K: Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem. Pharmacol. (2005) 70(7):1104-1113.
68. CUNDY KC, PETTY BG, FLAHERTY J et al.: Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (1995) 39(6):1247-1252.
69. CUNDY KC: Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. (1999) 36(2):127-143.
70. CIHLAR T, LIN DC, PRITCHARD JB et al.: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. (1999) 56(3):570-580.
71. HO ES, LIN DC, MENDEL DB, CIHLAR T: Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. (2000) 11(3):383-393.
72. LASKIN OL, DE MIRANDA P, KING DH et al.: Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob. Agents Chemother. (1982) 21(5):804-807.
73. DE BONY F, TOD M, BIDAULT R et al.: Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob. Agents Chemother. (2002) 46(2):458-463.
74. HEDAYA MA, ELMQUIST WF, SAWCHUK RJ: Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm. Res. (1990) 7(4):411-417.
75. TAKEDA M, KHAMDANG S, NARIKAWA S et al.: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. (2002) 300(3):918-924.
76. BIDIVILLE J, ROCH-RAMEL F: Competition of organic anions for furosemide and p-aminohippurate secretion in the rabbit. J. Pharmacol. Exp. Ther. (1986) 237(2):636-643.
77. GEMBA M, TANIGUCHI M, MATSUSHIMA Y: Effect of bumetanide on p-aminohippurate transport in renal cortical slices. J. Pharmacobiodyn. (1981) 4(3):162-166.
78. CHENNAVASIN P, SEIWELL R, BRATER DC, LIANG WM: Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int. (1979) 16(2):187-195.
79. HOOK JB, WILLIAMSON HE: Influence of probenecid and alterations in acid-base balance of the saluretic activity of furosemide. J. Pharmacol. Exp. Ther. (1965) 149(3):404-408.
80. GUSTAFSON JH, BENET LZ: Saturable kinetics of intravenous chlorothiazide in the rhesus monkey. J. Pharmacokinet. Biopharm. (1981) 9(4):461-476.
81. MASEREEUW R, MOONS WM, RUSSEL FG: Saturable accumulation and diuretic activity of hydrochlorothiazide in the isolated perfused rat kidney. Pharmacology (1997) 54(1):33-42.
82. VREE TB, VAN DEN BIGGELAAR-MARTEA M, VERWEY-VAN WISSEN CP: Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br. J. Clin. Pharmacol. (1995) 39(6):692-695.
83. ODLIND B, BEERMANN B: Renal tubular secretion and effects of furosemide. Clin. Pharmacol. Ther. (1980) 27(6):784-790.
84. HASANNEJAD H, TAKEDA M, TAKI K et al.: Interactions of human organic anion transporters with diuretics. J. Pharmacol. Exp. Ther. (2004) 308(3):1021-1029.
85. ERALY SA, VALLON V, VAUGHN DA et al.: Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knockout mice. J. Biol. Chem. (2006) 281(8):5072-5083.
86. KREMER JM, HAMILTON RA: The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J. Rheumatol. (1995) 22(11):2072-2077.
87. LIEGLER DG, HENDERSON ES, HAHN MA, OLIVERIO VT: The effect of organic acids on renal clearance of methotrexate in man. Clin. Pharmacol. Ther. (1969) 10(6):849-857.
88. FRENIA ML, LONG KS: Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann. Pharmacother. (1992) 26(2):234-237.
89. THYSSA, MILANO G, KUBAR J, NAMER M, SCHNEIDER M: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet (1986) 1(8475):256-258.
90. TAKEDA M, KHAMDANG S, NARIKAWA S et al.: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. (2002) 302(2):666-671.
91. HOOIJBERG JH, BROXTERMAN HJ, KOOL M et al.: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. (1999) 59(11):2532-2535.
92. KHAMDANG S, TAKEDA M, NOSHIRO R et al.: Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. (2002) 303(2):534-539.
93. SOMOGYI A, HEINZOW B: Cimetidine reduces procainamide elimination. N. Engl. J. Med. (1982) 307(17):1080.
94. SOMOGYI A, GUGLER R: Clinical pharmacokinetics of cimetidine. Clin. Pharmacokinet. (1983) 8(6):463-495.
95. SOMOGYI A, MCLEAN A, HEINZOW B: Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur. J. Clin. Pharmacol. (1983) 25(3):339-345.
96. SOMOGYI A, MUIRHEAD M: Pharmacokinetic interactions of cimetidine 1987. Clin. Pharmacokinet. (1987) 12(5):321-366.
97. 2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. (2005) 315(1):337-345.
98. MOTOHASHI H, UWAI Y, HIRAMOTO K, OKUDA M, INUI K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur. J. Pharmacol. (2004) 503(1-3):25-30.
99. ZHANG X, GROVES CE, BAHN A et al.: Relative contribution of OAT and OCT transporters to organic electrolyte transport in rabbit proximal tubule. Am. J. Physiol. Renal Physiol. (2004) 287(5):F999-F1010.
100. SOMOGYI A, STOCKLEY C, KEAL J, ROLAN P, BOCHNER F: Reduction of metformin renal tubular secretion by cimetidine in man. Br. J. Clin. Pharmacol. (1987) 23(5):545-551.
101. DRESSER MJ, XIAO G, LEABMAN MK, GRAV AT, GIACOMINI KM: Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm. Res. (2002) 19(8):1244-1247.
102. KIMURA N, OKUDA M, INUI K: Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm. Res. (2005) 22(2):255-259.
103. SOMOGYI AA, HOVENS CM, MUIRHEAD MR, BOCHNER F: Renal tubular secretion of amiloride and its inhibition by cimetidine in humans and in an animal model. Drug Metab. Dispos. (1989) 17(2):190-196.
104. BIERMANN J, LANG D, GORBOULEV V et al.: Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am. J. Physiol. Cell Physiol. (2006) 290(6):C1521-C1531.
105. SOMOGYI AA, BOCHNER F, SALLUSTIO BC: Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin. Pharmacol. Ther. (1992) 51(4):379-387.
106. KOSOGLOU T, ROCCI ML Jr, VLASSES PH: Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Clin. Pharmacol. Ther. (1988) 44(4):467-477.
107. VLASSES PH, KOSOGLOU T, CHASE SL et al.: Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. Arch. Intent. Med. (1989) 149(6):1350-1353.
108. HINDERLING PH, HARTMANN D: Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther. Drug Monit. (1991) 13(5):381-401.
109. KAWAHARA M, SAKATA A, MIYASHITA T, TAMAI I, TSUJI A: Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J. Pharm. Sci. (1999) 88(12): 1281-1287.
110. DURR D, STIEGER B, KULLAK-UBLICK GA et al.: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. (2000) 68(6):598-604.
111. DELANNOY IA, SILVERMAN M: The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. (1992) 189(1):551-557.
112. HAGER WD, FENSTER P, MAYERSOHN M et al.: Digoxin-quinidine interaction. Pharmacokinetic evaluation. N. Engl. J. Med. (1979) 300(22):1238-1241.
113. HEDMAN A, ANGELIN B, ARVIDSSON A, DAHLQVIST R, NILSSON B: Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin. Pharmacol. Ther. (1990) 47(1):20-26.
114. JOGESTRAND T, SCHENCK-GUSTAFSSON K, NORDLANDER R, DAHLQVIST R: Quinidine-induced changes in serum and skeletal muscle digoxin concentration; evidence of saturable binding of digoxin to skeletal muscle. Eur. J. Clin. Pharmacol. (1984) 27(5):571-575.
115. SCHENCK-GUSTAFSSON K, JOGESTRAND T, BRODIN LA, NORDLANDER R, DAHLQVIST R: Cardiac effects of treatment with quinidine and digoxin, alone and in combination. Am. J. Cardiol. (1983) 51(5):777-782.
116. TANIGAWARA Y, OKAMURA N, HIRAI M et al.: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. (1992) 263(2):840-845.
117. FROMM MF, KIM RB, STEIN CM, WILKINSON GR, RODEN DM: Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation (1999) 99(4):552-557.
118. DING R, TAYROUZ Y, RIEDEL KD et al.: Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. (2004) 76(1):73-84.
119. GUTMANN H, FRICKER G, DREWE J, TOEROEK M, MILLER DS: Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. (1999) 56(2):383-389.
120. DREWE J, GUTMANN H, FRICKER G et al.: HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC-833. Biochem. Pharmacol. (1999) 57(10):1147-1152.
121. ITO S, WOODLAND C, HARPER PA, KOREN G: The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1). Life Sci. (1993) 53(24):PL399-PL403.
122. VERSCHRAAGEN M, KOKS CH, SCHELLENS JH, BEIJNEN JH: P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res. (1999) 40(4):301-306.
123. PEDERSEN KE, DORPH-PEDERSEN A, HVIDT S, KLITGAARD NA, NIELSEN-KUDSK F: Digoxin-verapamil interaction. Clin. Pharmacol. Ther. (1981) 30(3):311-316.
124. OKAMURA N, HIRAI M, TANIGAWARA Y et al.: Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J. Pharmacol. Exp. Ther. (1993) 266(3):1614-1619.
125. WAKASUGI H, YANO I, ITO T et al.: Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin. Pharmacol. Ther. (1998) 64(1):123-128.
126. HIRATA S, IZUMI S, FURUKUBO T et al.: Interactions between clarithromycin and digoxin in patients with end-stage renal disease. Int. J. Clin. Pharmacol. Ther. (2005) 43(1):30-36.
127. KIRAN N, AZAM S, DHAKAM S: Clarithromycin induced digoxin toxicity: case report and review. J. Pak. Med. Assoc. (2004) 54(8):440-441.
128. RENGELSHAUSEN J, GOGGELMANN C, BURHENNE J et al.: Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br. J. Clin. Pharmacol. (2003) 56(1):32-38.
129. XU H, RASHKOW A: Clarithromycin-induced digoxin toxicity: a case report and a review of the literature. Conn. Med. (2001) 65(9):527-529.
130. WOODLAND C, VERJEE Z, GIESBRECHT E, KOREN G, ITO S: The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. J. Pharmacol. Exp. Ther. (1997) 283(1):39-45.
131. JALAVA KM, PARTANEN J, NEUVONEN PJ: Itraconazole decreases renal clearance of digoxin. Ther. Drug Monit. (1997) 19(6):609-613.
132. WOODLAND C, ITO S. KOREN G: A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Ther. Drug Monit. (1998) 20(2):134-138.
133. BACHMAKOV I, REKERSBRINK S, HOFMANN U, EICHELBAUM M, FROMM MF: Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. (2005) 371(3):195-201.
134. WANDEL C, KIM RB, KAJIJI S et al.: P-glycoprotein and cytochrome P450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. (1999) 59(16):3944-3948.
135. OCHELTREE SM, SHEN H, HU Y et al.: Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice. J. Pharmacol. Exp. Ther. (2004) 308(2):462-467.
136. SHU C, SHEN H, HOPFER U, SMITH DE: Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. Drug Metab. Dispos. (2001) 29(10):1307-1315.
137. BLEASBY K, HALL LA, PERRY JL, MOHRENWEISER HW, PRITCHARD JB: Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J. Pharmacol. Exp. Ther. (2005) 314(2):923-931.
138. LEABMAN MK, HUANG CC, KAWAMOTO M et al.: Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 12(5):395-405.
139. ERDMAN AR, MANGRAVITE LM, URBAN TJ et al.: The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am. J. Physiol. Renal Physiol. (2006) 290(4):F905-F912.
140. MARZOLINI C, PAUS E, BUCLIN T, KIM RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. (2004) 75(1):13-33.
141. ENGEL K, WANG J: Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol. Pharmacol. (2005) 68(5):1397-1407.
142. ENGEL K, ZHOU M, WANG J: Identification and characterization of a novel monoamine transporter in the human brain. J. Biol. Chem. (2004) 279(48):50042-50049.
143. TAKEDA M, BABU E, NARIKAWA S, ENDOU H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur. J. Pharmacol. (2002) 438(3):137-142.
144. MULATO AS, HO ES, CIHLAR T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J. Pharmacol. Exp. Ther. (2000) 295(1):10-15.
145. KHAMDANG S, TAKEDA M, SHIMODA M et al.: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J. Pharmacol. Sci. (2004) 94(2):197-202.
146. SRIMAROENG C, JUTABHA P, PRITCHARD JB, ENDOU H, CHATSUDTHIPONG V: Interactions of stevioside and steviol with renal organic anion transporters in S2 cells and mouse renal cortical slices. Pharm. Res. (2005) 22(6):858-866.
147. ISLINGER F, GEKLE M, WRIGHT SH: Interaction of 2,3-dimercapto-1-propane sulfonate with the human organic anion transporter hOATL1. Pharmacol. Exp. Ther. (2001) 299(2):741-747.
148. TAHARA H, KUSUHARA H, MAEDA K et al.: Inhibition of OAT3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab. Dispos. (2006) 34(5):743-747.
149. CHA SH, SEKINE T, FUKUSHIMA JI et al.: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. (2001) 59(5):1277-1286.
150. KIMURA H, TAKEDA M, NARIKAWA S et al.: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J. Pharmacol. Exp. Ther. (2002) 301(1):293-298.
151. BOURDET DL, PRITCHARD JB, THAKKER DR: Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther. (2005) 315(3):1288-1297.
152. CIARIMBOLI G, LUDWIG T, LANG D et al.: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. (2005) 167(6):1477-1484.
153. GORBOULEV V, ULZHEIMER JC, AKHOUNDOVA A et al.: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. (1997) 16(7):871-881.
154. BUSCH AE, KARBACH U, MISKA D et al.: Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol. Pharmacol. (1998) 54(2):342-352.
155. +)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J. Pharmacol. Exp. Ther. (1999) 291(2):778-784.
156. GANAPATHY ME, HUANG W, RAJAN DP et al.: β-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J. Biol. Chem. (2000) 275(3):1699-1707.
157. HAN HK, RHIE JK, OH DM et al.: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J. Pharm. Sci. (1999) 88(3):347-350.
158. BALIMANE PV, TAMAI I, GUO A et al.: Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. (1998) 250(2):246-251.
159. GANAPATHY ME, HUANG W, WANG H, GANAPATHY V, LEIBACH FH: Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. (1998) 246(2):470-475.
160. GUO A, HU P, BALIMANE PV, LEIBACH FH, SINKO PJ: Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J. Pharmacol. Exp. Ther. (1999) 289(1):448-454.
161. +/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm. Res. (1999) 16(1):55-61.
162. +/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur. J. Pharm. Biopharm. (2005) 59(1):17-24.
163. +/peptide cotransporter 2 causes a complete loss of transport function. Biochem. Biophys. Res. Commun. (2004) 316(2):416-420.
164. GANAPATHY ME, BRANDSCH M, PRASAD PD, GANAPATHY V, LEIBACH FH: Differential recognition of β-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J. Biol. Chem. (1995) 270(43):25672-25677.
165. GANAPATHY ME, PRASAD PD, MACKENZIE B, GANAPATHY V, LEIBACH FH: Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochim. Biophys. Acta (1997) 1324(2):296-308.
166. GAO J, MURASE O, SCHOWEN RL, AUBE J, BORCHARDT RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm. Res. (2001) 18(2):171-176.
167. VAN DER SANDT IC, BLOM-ROOSEMALEN MC, DE BOERAG, BREIMER DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur. J. Pharm. Sci. (2000) 11(3):207-214.
168. SPOELSTRA EC, WESTERHOFF HV, DEKKER H, LANKELMA J: Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur. J. Biochem. (1992) 207(2):567-579.
169. MAKHEY VD, GUO A, NORRIS DA et al.: Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm. Res. (1998) 15(8):1160-1167.
170. WALLE UK, WALLE T: Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab. Dispos. (1998) 26(4):343-346.
171. TAUB ME, PODILA L, ELY D, ALMEIDA I: Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab. Dispos. (2005) 33(11):1679-1687.
172. BALIMANE PV, PATEL K, MARINO A, CHONG S: Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur. J. Pharm. Biopharm. (2004) 58(1):99-105.
173. HUNTER J, JEPSON MA, TSURUO T, SIMMONS NL, HIRST BH: Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. (1993) 268(20):14991-14997.
174. POLLI JW, JARRETT JL, STUDENBERG SD et al: Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. (1999) 16(8):1206-1212.
175. EKINS S, KIM RB, LEAKE BF et al: Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. (2002) 61(5):974-981.
176. WOODAHL EL, YANG Z, BUI T, SHEN DD, HO RJ: MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS (2005) 19(15):1617-1625.
177. EKINS S, KIM RB, LEAKE BF et al.: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol. (2002) 61(5):964-973.
178. WANG EJ, LEW K, CASCIANO CN, CLEMENT RP, JOHNSON WW: Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother. (2002) 46(1):160-165.
179. FRICKER G, DREWE J, HUWYLER J, GUTMANN H, BEGLINGER C: Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. (1996) 118(7):1841-1847.
180. SAEKI T, UEDA K, TANIGAWARA Y, HORI R, KOMANO T: Human P-glycoprotein transports cyclosporin A and FK-506. J. Biol. Chem. (1993) 268(9):6077-6080.
181. YOKOGAWA K, TAKAHASHI M, TAMAI I et al.: P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm. Res. (1999) 16(8):1213-1218.
182. BOGMAN K, ZYSSET Y, DEGEN L et al.: P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Clin. Pharmacol. Ther. (2005) 77(1):24-32.
183. COLLETT A, HIGGS NB, SIMS E, ROWLAND M, WARHURST G: Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J. Pharmacol. Exp. Ther. (1999) 288(1):171-178.
184. PETRI N, TANNERGREN C, RUNGSTAD D, LENNERNAS H: Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm. Res. (2004) 21(8):1398-1404.
185. STEPHENS RH, O'NEILL CA, WARHURST A et al.: Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. (2001) 296(2):584-591.
186. WOLF DC, HORWITZ SB: P-glycoprotein transports corticosterone and is photoaffinity-Iabeled by the steroid. Int. J. Cancer (1992) 52(1):141-146.
187. WILLIAMS GC, LIU A, KNIPP G, SINKO PJ: Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob. Agents Chemother. (2002) 46(11):3456-3462.
188. BAKOS E, EVERS R, SINKO E et al.: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. (2000) 57(4):760-768.
189. SRINIVAS RV, MIDDLEMAS D, FLYNN P, FRIDLAND A: Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob. Agents Chemother. (1998) 42(12):3157-3162.
190. RENES J, DE VRIES EG, NIENHUIS EF, JANSEN PL, MULLER M: ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. (1999) 126(3):681-688.
191. KANG YH, LEE E, YOUK HJ et al.: Potentiation by α-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells. Cancer Lett. (2005) 217(2):181-190.
192. LEIER I, JEDLITSCHKY G, BUCHHOLZ U et al: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. (1994) 269(45):27807-27810.
193. JEDLITSCHKY G, LEIER I, BUCHHOLZ U et al.: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. (1996) 56(5):988-994.
194. LEIER I, HUMMEL-EISENBEISS J, CUI Y, KEPPLER D: ATP-dependent para-aminohippurare transport by apical multidrug resistance protein MRP2. Kidney Int. (2000) 57(4):1636-1642.
195. CUI Y, KONIG J, BUCHHOLZ JK et al.: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. (1999) 55(5):929-937.
196. GUO A, MARINARO W, HU P, SINKO PJ: Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab. Dispos. (2002) 30(4):457-463.
197. FLANAGAN SD, CUMMINS CL, SUSANTO M et al.: Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology (2002) 64(3):126-134.
198. KAWABE T, CHEN ZS, WADA M et al.: Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. (1999) 456(2):327-331.
199. HORIKAWA M, KATO Y, TYSON CA, SUGIYAMA Y: The potential for an interaction be ween MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab. Pharmacokinet. (2002) 17(1):23-33.
200. ZENG H, LIU G, REA PA, KRUH GD: Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. (2000) 60(17):4779-4784.
201. ZELCER N, SAEKIT, REID G, BEIJNEN JH, BURST P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J. Biol. Chem. (2001) 276(49):46400-46407.
202. CHEN ZS, LEE K, KRUH GD: Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. (2001) 276(36):33747-33754.
203. LAI L, TAN TM: Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem. J. (2002) 361(Pt 3):497-503.
204. CHEN ZS, LEE K, WALTHER S et al.: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. (2002) 62(11):3144-3150.
205. REID G, WIELINGA P, ZELCER N et al.: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. USA (2003) 100(16):9244-9249.
206. MARINO EL, DOMINGUEZ-GIL A: The pharmacokinetics of cefadroxil associated with probenecid. Int. J. Clin. Pharmacol. Ther. Toxicol. (1981) 19(11):506-508.
207. REGAMEY C, LIBKE RD, CLARKE JT, KIRBY WM: Pharmacokinetics of parenteral sodium cephalexin in comparison with cephalothin and cefazolin. Infection (1974) 2(3):132-136.
208. GRIFFITH RS, BLACK HR, BRIER GL, WOLNY JD: Effect of probenecid on the blood levels and urinary excretion of cefamandole. Antimicrob. Agents Chemother. (1977) 11(5):809-812.
209. GISCLON LG, BOYD RA, WILLIAMS RL, GIACOMINI KM: The effect of probenecid on the renal elimination of cimetidine. Clin. Pharmacol. Ther. (1989) 45(4):444-452.
210. ROBERTS DH, KENDALL MJ, JACK DB, WELLING PG: Pharmacokinetics of cephradine given intravenously with and without probenecid. Br. J. Clin. Pharmacol. (1981) 11(6):561-564.
211. VERHAGEN CA, MATTIE H, VAN STRIJEN E: The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br. J. Clin. Pharmacol. (1994) 37(2):193-197.
212. JACOBS C, COLEMAN CN, RICH L, HIRST K, WEINER MW: Inhibition of cis-diamminedichloroplarinum secretion by the human kidney with probenecid. Cancer Res. (1984) 44(8):3632-3635.
213. INOTSUME N, NISHIMURA M, NAKANO M, FUJIYAMA S, SATO T: The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J. Clin. Pharmacol. (1990) 30(1):50-56.
214. YASUI-FURUKORI N, UNO T, SUGAWARA K, TATEISHI T: Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin. Pharmacol. Ther. (2005) 77(1):17-23.
215. MASSARELLA JW, NAZARENO LA, PASSE S, MIN B: The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. Pharm. Res. (1996) 13(3):449-452.
216. CIMOCH PJ, LAVELLE J, POLLARD R et al.: Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1998) 17(3):227-234.
217. JAEHDE U, SORGEL F, REITER A et al.: Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin. Pharmacol. Ther. (1995) 58(5):532-541.
218. WALLER ES, SHARANEVYCH MA, YAKATAN GJ: The effect of probenecid on nafcillin disposition. J. Clin. Pharmacol. (1982) 22(10):482-489.
219. ITOH T, WATANABE N, ISHIDA M et al.: Stereoselective disposition of sulbenicillin in humans. Antimicrob. Agents Chemother. (1998) 42(2):325-331.
220. HARDY BG, SCHENTAG JJ: Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int. J. Clin. Pharmacol. Ther. Toxicol. (1988) 26(8):388-391.
221. VAN CRUGTEN J, BOCHNER F, KEAL J, SOMOGYI A: Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J Pharmacol. Exp. Ther. (1986) 236(2):481-487.
222. SHIGA T, HASHIGUCHI M, URAE A, KASANUKI H, RIKIHISA T: Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin. Pharmacol. Ther. (2000) 67(3):222-228.
223. FLETCHER CV, HENRY WK, NOORMOHAMED SE, RHAME FS, BALFOUR HH Jr: The effect of cimetidine and ranitidine administration with zidovudine. Pharmacotherapy (1995) 15(6):701-708.
224. MUIRHEAD M, BOCHNER F, SOMOGYI A: Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption. J. Pharmacol. Exp. Ther. (1988) 244(2):734-739.
225. SOMOGYI A, BOCHNER F: Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br. J. Clin. Pharmacol. (1984) 18(2):175-181.
226. BAUER LA, BLACK DJ, LILL JS et al.: Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances. Antimicrob. Agents Chemother. (2005) 49(4):1649-1651.
227. CHATTON JY, MUNAFO A, CHAVE JP et al.: Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br. J. Clin. Pharmacol. (1992) 34(6):551-554.
228. KOVARIK JM, RIGAUDY L, GUERRET M, GERBEAU C, ROST KL: Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin. Pharmacol. Ther. (1999) 66(4):391-400.
229. DORIAN P, STRAUSS M, CARDELLA C et al.: Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment. Clin. Invest. Med. (1988) 11(2):108-112.
230. BELZ GG, DOERING W, MUNKES R, MATTHEWS J: Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin. Pharmacol. Ther. (1983) 33(4):410-417.
231. PETERSEN P, KASTRUP J, BARTRAM R, MOLHOLM HANSEN J: Digoxin-trimethoprim interaction. Acta Med. Scand. (1985) 217(4):423-427.
232. KAUKONEN KM, OLKKOLA KT, NEUVONEN PJ: Itraconazole increases plasma concentrations of quinidine. Clin. Pharmacol. Ther. (1997) 62(5):510-517.